Trial of IDH305 in IDH1 Mutant Grade II or III Glioma
The purpose of this study is to found out if the drug IDH305 is safe and effective in subjects with IDH1 mutant grade II or III glioma that has progressed after observation or radiation therapy.
Glioma
DRUG: IDH305
Radiographic response rate, up to 8 weeks
Safety (adverse events) of the protocol therapy, The adverse events are evaluated per Common Terminology Criteria for Adverse Events (CTCAE) 4.03, up to 2 years|Volumetric radiographic response rate, up to 6 months|Median duration of response, up to 6 months|Median progression-free survival (PFS), up to 6 months|Progression-free survival at 6 months (PFS6), up to 6 months|2-year overall survival (OS), up to 2 years
IDH305 is an orally available, brain-penetrant, mutant-selective allosteric IDH1 inhibitor that blocks mutant IDH1-dependent production of 2-HG.